Fight like a Pro, with the Prolaris® Prostate Cancer Prognostic Test

The Prolaris Test is an advanced genetic test that combines tools like Gleason score and PSA with a personalized tumor score to determine how aggressive your prostate cancer is. The Prolaris Test helps you and your doctor decide the best treatment option based on your individual cancer.

Fight like a Pro, with the Prolaris® Prostate Cancer Prognostic Test

The Prolaris Test is an advanced genetic test that combines tools like Gleason score and PSA with a personalized tumor score to determine how aggressive your prostate cancer is. The Prolaris Test helps you and your doctor decide the best treatment option based on your individual cancer.

plays Prolaris explainer videolightbox

Is the Prolaris Test right for me?

Prostate cancer is personal and treatment should be too. The Prolaris Test is for any newly diagnosed man with prostate cancer and helps patients and providers answer pressing clinical questions like:

  • Are you an appropriate candidate for active surveillance or do you need treatment?
  • Is your cancer at risk of spreading?
  • What are your chances of surviving prostate cancer?
  • Can I benefit from adding hormone therapy (ADT) to radiation or can I appropriately avoid the side-effects of ADT?

Get our free testing guide

65%

In two clinical utility studies, Prolaris Test results led to change in management in up to 65% of patients.1,2,3

2x

The Prolaris Test score is 2x more prognostic than PSA and Gleason score combined4

$0

Majority of patients face no out-of-pocket costs for the Prolaris Test.5

Prolaris Test Patient story

Watch how Richard and his doctor worked together to decide on the best treatment option for him based on his Prolaris Test results.

Prolaris Test Patient story

Watch how Richard and his doctor worked together to decide on the best treatment option for him based on his Prolaris Test results.

Prostate Cancer can be a Hereditary Cancer

You may have inherited more than just your eye color from your parents

The MyRisk® Hereditary Cancer Test is a genetic test that identifies hereditary (germline) mutations to determine if you may have an inherited form of cancer. The MyRisk Test helps high-risk or metastatic prostate cancer patients qualify for new, personalized treatments – like targeted medications, clinical trials or if you have an elevated risk of developing a secondary cancer.

Request test kit

Genetic insights that guide cancer treatment through every step of the journey

  • for newly diagnosed and untreated patients

    The Prolaris Test is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to determine if a patient may be appropriate to watch their cancer in favor of active surveillance or if they should pursue treatment.

  • for patients with a family history of cancer and/or advanced disease

    The MyRisk Test screens for genetic variants linked to inherited cancers, helping identify individuals at increased risk based on their personal or family history. It can also assist in selecting patients for targeted therapies like PARP inhibitors and immunotherapy.

  • for advanced patients

    A somatic test that assesses 500+ genes, as well as key biomarkers like MSI, TMB and PD-L1, to determine if a patient’s tumor may be appropriate for novel therapies or clinical trials.

Previous Test
    Next Test

    Myriad is here for you

    Contact our trusted advisors for personalized support.

    Learn how genetic testing can provide better answers for the best prostate cancer treatment for you in our FREE Patient Testing Guide.

    References:

    1. Crawford ED, Scholz MC, Kar AJ, et al. Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer:Results From an Ongoing Registry. Curr Med Res Opin 2014; 1-7
    2. Shore, N D., et al. Impact of the cell cycle progression test of physician and patient treatment selection for localized prostate cancer. The Journal of Urology 2016;195(3),612- 618
    3. Lin, D. W., et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations. 2018; doi: 10.1016/j.urolonc.2018.03.011.
    4. Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. BJC 2012;106(6):1095-1099
    5. Based on a review of 12 months of past claim data for major insurance carriers across the US, the majority of patients face no out-of-pocket costs for their Prolaris test. Last updated 2024.

    ©2025 Myriad Genetics, Inc. Myriad Genetics, MyRisk, Precise Tumor, Prolaris and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.